New drug combo targets tough lung cancer mutation

NCT ID NCT03170206

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested two oral drugs, palbociclib and binimetinib, in 34 people with advanced lung cancer that has a specific change in the KRAS gene. The goal was to find the safest dose and see if the combination can slow cancer growth. The study is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palbociclib and binimetinib (two oral drugs that block cell growth signals)
What this could lead to: If this combination works, it could offer a new treatment option for people with a hard-to-treat form of lung cancer driven by a KRAS mutation.
What could go wrong: This is an early Phase 1 trial with only 34 participants, so it is primarily testing safety and dosing. The drugs may cause side effects and may not shrink tumors or extend life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED KRAS MUTANT NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.